GnRH激动剂与睾丸切除术治疗晚期前列腺癌的代谢后果:一项随机临床研究
主要终点空腹血糖变化无组间差异;睾丸切除术组总脂肪量、皮下脂肪和体重增加更显著,且脂肪增加与胰岛素抵抗增加中度相关。雄激素剥夺治疗整体导致体成分不良改变、胰岛素抵抗和胆固醇升高,12-24周即可出现。
要点
- 睾丸切除术相比GnRH激动剂导致更明显的脂肪堆积和体重增加。
- 脂肪量增加与胰岛素抵抗增加中度相关。
- 雄激素剥夺治疗12-24周即可出现体成分和代谢不良改变。
核心结论
- 雄激素剥夺治疗导致体成分不良改变、胰岛素抵抗增加和血清胆固醇升高,12-24周即可观察到。
- 睾丸切除术比GnRH激动剂引起更显著的脂肪积累,且与胰岛素抵抗增加相关。
主要发现
- 空腹血糖变化组间无差异:0.2 mmol/L(95%CI -0.1, 0.4;P=0.32)。
- 48周时睾丸切除术组总脂肪量增加+2.06 kg(95%CI 0.55, 3.56)、皮下脂肪增加+133 cm3(95%CI 22, 243)、体重增加+3.30 kg(95%CI 0.74, 5.87),均高于曲普瑞林组(P<0.05)。
- 脂肪量增加与胰岛素抵抗增加中度相关(P<0.001)。
- 内脏脂肪、瘦体重和android/gynoid脂肪比组间无差异。
- 合并分析显示雄激素剥夺治疗随时间显著增加脂肪量、皮下脂肪、内脏脂肪、血清总胆固醇、高密度脂蛋白和低密度脂蛋白及所有胰岛素抵抗指标,瘦体重较基线下降(均P<0.05)。
临床怎么用
- 对接受雄激素剥夺治疗的前列腺癌患者,应在治疗早期(12-24周内)监测体成分和代谢指标变化。
- 选择睾丸切除术时应考虑其相比GnRH激动剂更明显的脂肪堆积和胰岛素抵抗风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare the metabolic changes between men with advanced prostate cancer commenced on a gonadotropin-releasing hormone (GnRH) agonist and those treated with orchiectomy. PATIENTS AND METHODS: Fifty-eight hormone-naive men with advanced prostate cancer were randomly assigned (1:1) to either subcapsular orchiectomy or triptorelin 22.5 mg/24 week depot injections. The participants were followed for 48 weeks, with study visits at baseline, 12, 24 and 48 weeks. The primary endpoint was changes in fasting plasma glucose. Secondary endpoints included changes in body composition (i.e. weight, fat mass, visceral adipose tissue [VAT], subcutaneous adipose tissue [SAT], lean body mass [LBM] and android/gynoid fat [AG] ratio) assessed with dual X-ray absorptiometry, serum lipid profiles, and insulin resistance evaluated during an oral glucose tolerance test. Linear mixed models were used to analyse the between-group differences. RESULTS: No treatment differences in the changes in fasting plasma glucose (0.2 mmol/L, 95% confidence interval [CI] -0.1, 0.4; P = 0.32) were observed. The orchiectomy group experienced greater increases in total fat mass (+2.06 kg, 95% CI 0.55, 3.56), SAT (+133 cm3 , 95% CI 22, 243) and weight (+3.30 kg, 95% CI 0.74, 5.87) at 48 weeks than did the triptorelin group (all P < 0.05), with the increases in fat mass being moderately correlated with increases in insulin resistance (P < 0.001). No differences in changed VAT, LBM or AG ratio were observed between the groups. The pooled analyses, combining data from both groups, showed androgen deprivation therapy (ADT) to significantly increase fat mass, SAT, VAT, serum cholesterols (total, high-density lipoprotein and low-density lipoprotein) and all measures of insulin resistance over time, while LBM decreased as compared with baseline values (all P < 0.05). These changes were apparent after only 12-24 weeks of ADT. CONCLUSIONS: Androgen deprivation therapy leads to adverse changes in body composition and increased insulin resistance and serum cholesterols, with changes already observed after only 12-24 weeks of treatment. This study further demonstrates that orchiectomy causes greater increases in fat accumulation compared with GnRH agonists and that these increases are associated with an increase in insulin resistance.
引用
- Østergren PB, Kistorp C, Fode M, et al. Metabolic consequences of gonadotropin-releasing hormone agonists vs orchiectomy: a randomized clinical study. BJU Int. 2018. PMID: 30388320. doi:10.1111/bju.14609
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。